| abstract |
The present invention relates to novel chemical entities that act as thromboxane (TX) A2 receptors, or T prostanoid receptor (TP) antagonists, as well as thromboxane (TX) A, and endoperoxide prostaglandin (PG) G2. / PGH2, acts as an incidental ligand for TP, including 20-hydroxyeicosatetraenoic acid (20-HETE) and free radical derived isoprostanes (eg, 8-iso-prostaglandin (PG) F2α) i It relates to their use in the treatment of human diseases where every other agent plays a role. The compounds of the present invention preferably comprise benzene substituted with a substituted biphenylyloxy group (eg at the 2-position), substituted with a nitrile group (eg at the 5-position) and comprising benzenesulfonylurea, The compounds show promising results as TP-isoform selective TP antagonists. |